Company profile: Ultima Genomics
1.1 - Company Overview
Company description
- Provider of a low-cost sequencing platform and related workflows, including the UG 100™ high-throughput system using a 200mm open silicon wafer with built-in automation; ppmSeq™ for rare event detection at one part per million for liquid biopsies and MRD; large-scale single-cell and spatial sequencing workflows; RNA-Seq for gene expression and isoform analysis; and genome-wide methylation sequencing compatible with standard tools.
Products and services
- PpmSeq™: Ultra-accurate sequencing method enabling rare event detection at one part per million, ideal for liquid biopsies and minimal residual disease monitoring
- Single Cell and Spatial Sequencing: Large-scale tools and workflows for single cell RNA-seq and spatial genomics, compatible with leading library prep and downstream processing tools
- UG 100™: Wafer-scale sequencing platform using a 200mm open silicon wafer to deliver high-throughput, cost-effective runs with built-in automation for continuous operation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ultima Genomics
Correlagen
HQ: United States
Website
- Description: Provider of genetic testing that helps physicians diagnose diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Correlagen company profile →
Biocartis
HQ: Switzerland
Website
- Description: Provider of a diagnostics technology platform for multiplexed detection of bio‑analytes, focused on integrated molecular and immunodiagnostics via a proprietary micro‑technology platform. Products include the Idylla fully automated sample‑to‑result real‑time PCR system for molecular diagnostics from various biological samples, and assays such as APIS ESR1, Idylla BRAF, GeneFusion (research use), ctEGFR, and NRAS‑BRAF‑EGFR S492R.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocartis company profile →
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rome Therapeutics company profile →
LGC
HQ: United Kingdom
Website
- Description: Provider of life sciences measurement and testing solutions, delivering reference materials, genomics and agbio solutions, clinical and molecular diagnostics, analytical testing, and food and water safety testing, plus government partnership services for evidence-based decision-making, supported by expertise in regulation, accreditation, and standard setting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LGC company profile →
Neogen
HQ: United States
Website
- Description: Provider of food and animal safety products, developing, manufacturing and marketing a diverse line dedicated to food and animal safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ultima Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ultima Genomics
2.2 - Growth funds investing in similar companies to Ultima Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ultima Genomics
4.2 - Public trading comparable groups for Ultima Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →